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INTRODUCTION
The structure and the role of microvasculature has
been progressively clarified in this last decade (1, 2). We
now have adequate information on the time course and
percentage occurrence of microvascular obstruction
(MO). We know that the venules are the site of leukocyte
adhesion during inflammation and that their endothelial
surfaces express a number of adhesion molecules,
whose production is significantly up-regulated after the
onset of tissue injury (3). Similarly we know that about
one fifth to one third of patients with TIMI grade 3 flow
after mechanical or pharmacological reperfusion show
evidence of MO (4, 5) which, in turn, seems the basis of
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ABSTRACT: Background. About one third of patients with TIMI 3 after reperfusion have evi-
dence of microvascular obstruction (MO) which represents an independent predictor of my-
ocardial wall rupture. This explains all efforts made to prevent MO. Magnetic resonance imaging
(MRI) has proved to be particularly useful in detecting MO. The aim of this study was to evaluate
with MRI if different fibrinolytic regimens in acute myocardial infarction display different effects
on left ventricle (LV) volumes and ejection fraction (EF), as well as on myocardial infarct size
(MIsz) and MO. 
Methods. Twenty male patients, mean age 58 years, affected by acute myocardial infarction, ten
anterior and ten inferior, were treated with: full dose reteplase in ten, and half dose reteplase plus
full dose abciximab (R+Abcx) in the other ten patients. In the fourth day after hospital admission,
MRI STIR T2 images were used to quantify MIsz, while 2dflash cineloops were used after the in-
jection of gadolinium, to quantify LV volumes, EF and to detect MO.
Results. LV EF was higher in R+Abcx 51±10 than in reteplase 41±8. MIsz was similar in both
treatment groups: however a close relationship was present between MIsz and EF in the
reteplase group indicating that the greater the MIsz the lower the EF. In R+Abcx this relationship
was no longer present, suggesting a protective effect of the drug on microcirculation. In fact ex-
tensive MO was present in 25% of all cases, 80% of which in the reteplase group while only 20%
in R+Abcx.
Conclusion. R+Abcx prevents MO: compared to traditional fibrinolytic therapy it allows better
LV function and most likely improved long term survival. (Heart International 2006; 2: 54-65)
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intracardiac hemorrhage (6, 7) and of the development
of myocardial wall rupture (8).
In patients with acute coronary syndromes undergo-
ing PCI, aspiration of the coronary artery has revealed
thrombus with or without plaque components in 15-
50% of the patients (9-11). 
This means that in a large percentage of cases, 50-
85%, MO is a dynamic phenomenon which begins grad-
ually and progressively develops after the occluded
vessel has been reopened (12,13). It then persists for at
least 1 month after reopening of the epicardial coronary
artery, predicting worse scar thinning, infarct expan-
sion, poor survival, and ultimately annulling the effect of
PCI (14-16).
This explains all efforts made to prevent MO with me-
chanical devices (17,18) or with pharmacological strate-
gies (19-33). 
The rational of focusing downstream the open artery
hypothesis may be further emphasized by considering
that all cardiac ruptures, likely the main cause of death
in the in-hospital course of myocardial infarction, seem
to lag behind MO which represents a significant, and in
all probability the principal independent predictor of
cardiac rupture (34, 35). 
Magnetic Resonance Imaging (MRI) has proved to be
of great value in detecting and monitoring MO after oc-
clusion and reopening of the coronary artery, both in ex-
perimental and in vivo studies (36-46). It also provides
evidence of its value in recognizing myocardial hemor-
rhage and impending wall rupture, thus allowing a win-
dow of interventional opportunity in this often cata-
strophic event (8, 38, 47-55). 
The aim of this study was to evaluate, by means of
MRI, in subacute myocardial infarction, if the different
pharmacological strategies of GUSTO V reperfusion
protocol i.e. full dose reteplase vs half dose reteplase
plus full dose abciximab (R+Abcx) , display different ef-
fects on volumes and function of the left ventricle (LV),
as well as on miocardial infarct size (MIsz) and MO (29). 
SUBJECTS AND METHODS
From the list of consecutive patients randomized in
the GUSTO V study at our Institution, 20 male patients,
mean age 58 years range 37-75, were addressed, after
written consent, to MRI study in the 4th day of myocar-
dial infarction. 
Although selected from a progressive list, in agree-
ment with the criteria of GUSTO V (29) , the grid of MRI
studies was created to fulfil the following criteria: age
matched patients affected by anterior and posterior my-
ocardial infarctions , age matched patients treated with
reteplase or R+Abcx. The grid was thus composed of: 5
anterior treated with reteplase, 5 anterior treated with
R+Abcx, 5 inferior treated with reteplase, 5 inferior
treated with R+Abcx. All groups had an identical pain to
fibrinolytic therapy time. All patients had clinically un-
complicated and apparently reperfused myocardial in-
farction.
Statistical evaluation was made with SPSS 13.0 soft-
ware. 
Magnetic resonance protocol
Examinations were performed on a Somatom Vision
1.5T scanner (Siemens Erlangen Germany) and ana-
lyzed with the built-in Numaris cardiac software.
After initial ECG triggered turbo-flash scouts in axial
and in double oblique direction, STIR T2 breath hold
10mm thickness images, were obtained in four cham-
bers and in consecutive contiguous short axis views
(SAX), encompassing the whole LV from the base to the
apex. A complete three dimensional (3D) STIR T2 study
was then created by assembling all base to apex slices
in a 3D package, from which LV end diastolic volume
(EDV) and LV end diastolic mass could be calculated.
STIR T2 hyperintense signal was then manually outlined
in each SAX slice and subsequently 3D reconstructed to
obtain myocardial infarct size (MIsz), representative of
ischemic/infarcted myocardium. MIsz was expressed
as a percent of the entire LV mass (Fig. 1). In order to
quantify the degree of hypersignal level, a circular re-
gion of interest (ROI) of 0.5 cm diameter was positioned
in the center of STIR T2 hyperintense area and the value
was compared with a similar ROI positioned in a region
remote from the site of infarction. A dimensionless 
value, STIR Intensity ratio, was obtained to represent
the signal intensity on myocardial infarction.
A bolus of 0.2 mmol Gd-DTPA per kg body weight
(Magnevist, Schering-AG, Berlin, Germany) was then in-
jected. The same SAX positions of the STIR study were
repeated with 2D-flash cine sequences (2d-fl). By as-
sembling base to apex contiguous SAX 2d-fl cineloops,Microvascular obstruction in acute myocardial infarction
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a new 3D study was created from which EDV and ejec-
tion fraction (EF) were calculated as habitually done in
cardiac MRI procedure. 
As all T1 sequences, also 2d-fl is fit to visualize my-
ocardial signal void in the presence of MO with the limi-
tation of less contrasted images compared to more
dedicated T1 sequences, but with the advantage of be-
ing able to follow the MO dynamically during systole (8).
In order to visualize only persistent MO, 2d-fl acquisi-
tion started five minutes after Gd injection. Since delin-
eation and quantification of small MO was practically
unfeasible, MO was visually estimated and classified
as: not present (group 1), small subendocardial (group
2), and large or transmural (group 3).
Due to the limited time allowed for each patient, po-
tentially unstable in day four after myocardial infarction,
to the limited contrast gain in late enhancement imaging
of our present scanner, to the main goal of this study i.e.
to discover differences in volumes and EF, and also to
the still incomplete standardization of this technique for
quantification of infarct size, (56) late enhancement
quantification of infarct size was not performed. Thus
each study could be contained in 30 minutes, the time
allowed by the Ethical Committee of our Hospital for the
study of this type of patients.
The list of patients, treatment and measurement per-
formed is reported in Table I.
RESULTS
Table I sets out the list of patients with individual
measurements; in Table II the descriptive statistics in
both types of treatment; and in Table III the descriptive
statistics divided by drug regimen and site of myocar-
dial infarction.
Tables from IV to VII show the results of paired t-test
(2 tailed significance) for the two different regimens of
therapy.
As evident, mean values of MIsz, EF, Intensity Ratio
and EDV, were not statistically different in patients treat-
ed with reteplase and in those treated with R+Abcx.
Neither a further grouping for site of myocardial infarc-
tion provided additional differences. In spite of this,
mean value of EF in Abciximab was only slightly de-
pressed but clearly higher than that of the reteplase
group. So when a correlation was attempted with EF
and the other measures evaluated, it became clear that
Fig. 1 - From base (A)
to  apex  (F)  STIR  T2
contiguous slices. En-
docardial and epicar-
dial  contours  define
the  myocardial  slice
area from which a 3D
quantification  of  LV
mass can be obtained.
Similarly  contour  of
hypersignal  area  (A)
applied  to  all  slices,
creates the MIsz, ex-
pressed  in  %  of  LV
mass.Zoni et al
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TABLE I - LIST OF PATIENTS WITH INDIVIDUAL MEASUREMENTS
Name Age MI Drug STIR  2d-fl  STIR 2d-fl  2d-fl
3D MIsz % 3D EF % Intensity ratio 3D EDV mL MO 1-2-3
G.P. 48 Ant. R+Abcx 31 36 1.57 173 1
A.G.C. 71 Ant. R+Abcx 73 56 1.27 131 1
O.E. 67 Ant. R+Abcx 13 50 1.6 120 2
B.G. 62 Ant. R+Abcx 11 67 1.87 115 1
L.C.A. 60 Ant. R+Abcx 14 54 1.7 136 1
S.M. 53 Ant. Reteplase 19 44 1.65 145 2
N.M. 75 Ant. Reteplase 41 26 2.2 104 2
F.G. 45 Ant. Reteplase 26 35 1.82 237 1
F.L. 59 Ant. Reteplase 24 44 1.8 76 2
M.E. 72 Ant. Reteplase 24 43 1.5 187 1
M.C. 57 Inf. R+Abcx 36 34 1.98 225 1
P.D. 53 Inf. R+Abcx 39 60 1.67 149 1
A.U. 73 Inf. R+Abcx 17 42 1.96 132 3
G.G. 51 Inf. R+Abcx 35 56 1.39 221 2
S.G. 66 Inf. R+Abcx 20 53 1.94 93 2
G.F. 48 Inf. Reteplase 22 43 1.64 212 3
C.A. 63 Inf. Reteplase 22 45 1.75 160 3
P.S. 37 Inf. Reteplase 19 52 1.62 140 3
S.M. 37 Inf. Reteplase 17 49 1.93 142 1
S.S. 65 Inf. Reteplase 36 31 1.5 128 3
TABLE II - DESCRIPTIVE STATISTICS IN BOTH TYPES OF TREATMENTS
Drug Minimum Maximum Mean STD
R+Abcx age 48 73 60.8 8.5
STIR 3D MIsz % 11 73 28.9 18.7
2d-fl 3D EF 34 67 50.8 10.5
STIR Intensity ratio 1.27 2 1.7 0.2
2d-fl 3D EDVmL 93 225 149.5 44
Reteplase age 37 75 55.4 13.6
STIR 3D MIsz % 17 41 25 7.7
2d-fl 3D EF 26 52 41.2 8.1
STIR Intensity ratio 1.50 2.20 1.75 0.2
2d-fl 3D EDVmL 76 237 153.1 48.3
TABLE III - DESCRIPTIVE STATISTICS DIVIDED BY DRUG REGIMEN
Drug MI Age STIR  3D MIsz % 2d-fl 3D EF STIR 2d-fl
Intensity ratio 3D EDV mL
R+Abcx ant mean 61.6 28.4 52.6 1.6 135
STD 8.7 26.2 11.2 0.2 22.8
inf mean 60 29.4 49 1.8 164
STD 9.3 10.1 10.7 0.3 57.6
Total mean 60.8 28.9 50.8 1.7 149.5
STD 8.5 18.7 10.5 0.2 44.
Reteplase ant mean 60.8 26.8 38.4 1.8 149.8
STD 12.6 8.3 7.9 0.3 64.3
inf mean 50 23.2 44 1.7 156.4
STD 13.6 7.5 8.1 0.2 33.1
Total mean 55.4 25 41.2 1.8 153.1
STD 13.6 7.7 8.1 0.2 48.3Microvascular obstruction in acute myocardial infarction
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the linear regression between EF and MIsz was strongly
significant in the reteplase group. In this last, the larger
the MIsz, the lower the EF. This clear and expected 
correlation was no longer present in R+Abcx group with
EF completely unrelated to MIsz (Fig. 2).
Similarly, MO also showed a powerful relation to EF,
with the strongest correlation in group 3 of patients,
those with the greatest MO areas (Fig. 3). 
Large MO (group 3) was present in 25% of patients: i.e
5 out of 20. Four of these patients were in the reteplase
group whereas small subendocardial (group 2) MO, were
uniformly distributed in R+Abcx groups: see Table I.
Of note, two patients of this study died: C.A. and P.S.
both for wall rupture, both in the reteplase group and
TABLE IV - INFARCT  SIZE  (MIsz%)  AS  %  OF  THE  WHOLE,
THREE  DIMENSIONALLY  (3D)  CALCULATED,  MY-
OCARDIAL MASS
STIR Mean Standard Deviation Sig. (2-tailed)
3D MIsz %
R+Abcx 28.9 18.72 0.586
Reteplase 25.0 7.70
TABLE V - FROM CONTIGUOUS BASE TO APEX CINE 2d-flash
SLICES, THREE DIMENSIONAL (3D) EJECTION FRAC-
TION (EF) IS CALCULATED IN BOTH DRUG REGI-
MENS
2d-fl Mean Standard Deviation Sig. (2-tailed)
3D EF
R+Abcx 50.80 10.51 0.035
Reteplase 41.20 8.08
TABLE VI - RATIO  BETWEEN  INTENSITY  VALUES  OBTAINED
WITH STIR IMAGES, IN INFARCT AREA AND IN NOR-
MAL MYOCARDIUM, IN BOTH DRUG REGIMENS
STIR Mean Standard Deviation Sig. (2-tails)
Intensity ratio
R+Abcx 1.69 0.25 0.653
Reteplase 1.74 0.22
TABLE VII - END DIASTOLIC VOLUME (EDV), EXPRESSED IN
MILLILITERS(ML) OBTAINED FROM CINE 2D-FLASH
(2d-fl) SEQUENCES, IN BOTH DRUG REGIMENS
2d-fl 3D EDVmL Mean Standard Deviation Sig. (2-tailed)
R+Abcx 149.5 44.03 0.842
Reteplase 153.1 48.36
Fig. 2 - Inverse linear regression between  infarct size (MIsz%) ad
ejection fraction (2d-fl 3D EF) in both drug regimens. Details in the
text.
Fig. 3 - Relationship between microvascular obstruction (2d-fl
MO) infarct size (MIsz%) ad ejection fraction (2d-fl 3D EF). 1,2 and
3 represent: no MO, small MO and large MO respectively. Details in
the text.Zoni et al
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with severe (group 3) MO. The first patient who died in
day five, was the object of a previous publication (8).
The second suddenly died at home 7 days after uncom-
plicated myocardial infarction.
Finally, no significant correlations could be found
when patients were grouped according to the site of
myocardial infarction (Fig. 4).
DISCUSSION
The first consideration regards EF. As already known,
MRI 3D reconstruction of the LV carries a small variabil-
ity so that also a limited population can be sufficient to
disclose differences not revealed by echocardiography
(57-62). This is also the case of this 20 patient study, in
which mean EF in R+Abcx patients was clearly higher,
though  with  weak  significance,  compared  to  the
reteplase group. This occurred despite similar MIsz and
intensity ratio, indicating that different degrees of cell
Fig. 4 - Inverse linear regression between  infarct size (MIsz%)
ad ejection fraction (2d-fl 3D EF) according to the site of my-
ocardial infarction: anterior (Ant.) or inferior (Inf.). Details in the
text.
Fig. 5 - Short axis STIR
image of the left ventri-
cle (A) and the corre-
sponding macroscopic
autoptic specimen (C).
Subendocardial void of
signal  in  A  corre-
sponds to hemorrhagic
tissue in C, while hy-
persignal  in  A  corre-
sponds to edema in C.
(D)  small  red  cells
dominate the center of
hemorrhagic area (dark
subendocardium in C).
(B) in the area of ede-
ma  (white  area  in  C)
proceeding  from  the
inner (right-bottom) to
the  outer  (left-top)
plane:  the  number  of
unbroken  myocites
progressively increas-
es while the interstitial
space  progressively
reduces. Microvascular obstruction in acute myocardial infarction
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damage may be represented by similar STIR T2 signal,
which  thus  seems  unable  to  distinguish  irreversible
necrotic from reversible viable myocardium. This latter is
the prevalent condition in MIsz of patients treated with
R+Abcx. 
The traditional onion configuration of myocardial is-
chemia and infarction suggests that the outer layers are
less damaged than the inner myocardium. Under these
circumstances with increasing MIsz a progressive im-
pairment of the LV with lowering EF should be expected.
In the reteplase group in fact all this happened, as rep-
resented by the clear inverse relation between MIsz and
EF. This was the result of epicardial fibrinolysis, which
though successful, could not prevent the development of
MO. This was related, in our study with equivalent pain to
treatment time between groups (63) to the extent of MIsz
more than the success of epicardial trombolysis.
The above considerations were furthermore confirmed
by the opposite behaviour observed in R+Abcx patients
where not only epicardial but also microvascular vessels
were pharmacologically preserved. In these patients de-
spite unchanged MIsz compared to reteplase, the inverse
relationship of Figure 2 was completely lost and almost
no MO occurred. 
A second consideration arises from STIR T2- imaging
of myocardial infarction. 
Almost contemporaneously some years ago, two dif-
ferent works indicated that T2 weighted (64) and T1
weighted sequences (39) were able to define infarct ar-
eas with good correspondence with the infarct size ex-
pressed by Thallium irreversible defect. In experimental
comparison however (65), infarct areas seemed more
accurately  represented  by  T1  compared  to  those,
slightly overestimated, obtained with T2 sequences.
Nonetheless the same images also indicated that T2-
weighted could detect subendocardial void of signal not
visible in T1 sequence, indicating that two different tis-
sue were at the same time present in that infarct area,
both well detected by T2 approach. This closely calls
MRI experimental data which indicate that in the same
infarct area, irreversibly damaged myocites with patent
microcirculation and irreversibly damaged myocytes
with occluded microcirculation may coexist (12).
Since then, both T2 (66-68) and T1 late enhancement
imaging have been utilized to estimate infarct size, T1-
weighted largely dominating the scene (36, 39, 69-92). 
In spite of this, some limitations suggest that beyond
the clear experimental and clinical evidence of late en-
hancement usefulness, the exact quantification of infarct
size requires further technological, procedural and metho-
dological steps to be completely defined (56, 68, 74). 
In addition, void of signal in T2 images most likely in-
dicates hemorrhagic tissue, currently a prevalent do-
main of T2 imaging (93-96).
A comprehensive illustration of the above considera-
tions is reproduced in the cases: C.A. Figure 5 whose
imaging of wall rupture as been object of a previous
publication (8) and P.S. Figure 6 suddenly dead for wall
rupture as previously reported. 
Figure 5 shows C.A. STIR T2 short axis slice with
clear evidence of transmural hyperenhancement of the
inferior wall surrounding a subendocardial void of signal
Fig. 6 - Long axis  im-
ages of the left ventri-
cle in cine 2d-flash (A)
and  in  STIR  T2  se-
quence (B). 
Both  indicate  the
presence of MO, STIR
image  also  suggest-
ing  the  hemorrhagic
nature of MO. Com-
plete  description  in
the text.Zoni et al
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(A).  This  respectively  corresponds  to:  oedema  and
subendocardial haemorrhage in the macroscopic au-
toptic specimen (B). The histological aspect of those
layers indicate subendocardial red blood cells predom-
inance (D) and in (C) the extensive loss of myocytes in
the confining zone near the hemorrhagic endocardium,
progressively replaced in the outer layers by unbroken
myocytes and parallel reduction of “expanded“ intersti-
tium. This last happened without a clear modification of
signal intensity in hyperenhanced area of A Thus similar
or contiguous levels of T2 intensity, represents different
degrees of cell injure as already outlined in previous
MRI studies on ischemia necrosis hemorrhage and
healing tissue (97) 
In Figure 6 is represented the second case of wall
rupture: P.S. A long axis 2d-fl after Gadolinium injection
clearly demonstrate the presence of a long MO extended
from the base to the subepicardial inferior distal wall.
Both 2d-fl (A) and STIR T2 (B) images were able to identi-
fy the presence of severe MO, STIR T2 also suggesting
the haemorrhagic characteristics of MO, and 2d-fl allow-
ing to follow MO dynamically during systole, thus indicat-
ing its threatening extension towards the epicardium.
CONCLUSION 
R+Abcx prevents MO: compared to traditional fibri-
nolytic therapy, this allow a better LV function and most
likely an improved long term survival. 
Extensive MO was present and well recognized in
25% of all cases, 80% of which fall in the Reteplase
group of treatment. 
The combination of T1 dynamic 2d-flash cine and
STIR T2 sequences may allow recognition and tissue
characterisation of MO also suggesting the presence of
impending ruptures. 
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